



CON IL PATROCINIO



Secondo Incontro d'Autunno  
**4°** Congresso Nazionale  
Società Italiana di Rinologia



Presidente Onorario  
**Maurizio Iengo**

Presidente del Congresso  
**Gaetano Motta**

**NAPOLI,**  
**12-14 dicembre 2019**

Centro Congressi Federico II

Corso Satellite GCORL  
12 dicembre 2019

**LA CHIRURGIA DEL BASICRANIO:  
ATTUALE RUOLO DELL'ENDOSCOPIA NASALE**



NAPOLI,  
12-14 dicembre 2019  
Centro Congressi Federico II

AULA A

12:30 - 13:30

COMUNICAZIONI ORALI

DIAGNOSTICA CLINICA E STRUMENTALE

Moderatori: **E. Cantone, P. Cassano**

Alterazioni citologiche della mucosa nasale dopo il tamponamento nasale

**P. G. Marano, E. M.C. Trecca, F. Di Taranto, G. M. Russo, C. De Filippis, P. Cassano, M. Cassano**

La citologia nasale nel paziente laringectomizzato

**A. Armone Caruso, M.L. Romano, G. Motta, G. Salerno**

Chronic rhinosinusitis in cystic fibrosis patients: smell evaluation

**A. M. Di Lullo, P. Iacotucci, M. Comegna, P. Dolce, E. Cantone, M. Giugliano, G. Grimaldi, M. T. Guarino, R. Musto, C. Czaczkes, M. Cavaliere, M. Mesolella, M. Iengo**

Lo studio aerodinamico dell'insufficienza velo-faringea nella Sindrome da Delezione 22q11.2

**S. Motta, P. Piroli, G. Marcuccio, A. Quaremba**

Studio clinico retrospettivo sull'utilizzo della flucloxacillina vs. amoxicillina-acido clavulanico nelle flogosi acute delle vie aeree superiori

**S. Motta, G. Motta, D. Testa, M. Nunziata, G. Marcuccio, E. Cantone, M. Iengo**

Valutazione di olfatto, gusto e sapore in soggetti obesi

**E. M.C. Trecca, S. Spadavecchia, V. Nicastro, A. Altieri, P. G. Marano, F. Fortunato, M. Cassano**

Manometria naso sinusale: proposta di una tecnica innovativa

**B. Cassiano, M. Gamera**

VENERDI 13 DICEMBRE

# **CHRONIC RHINOSINUSITIS IN CYSTIC FIBROSIS PATIENTS: SMELL EVALUATION**

Antonella Miriam Di Lullo, MD PhD<sup>1,2\*</sup>, Paola Iacotucci, MD<sup>3</sup>,  
Marika Comegna, PhD<sup>2</sup>, Pasquale Dolce, PhD<sup>4</sup>, Elena Cantone,  
MD PhD<sup>1</sup>, Marta Giugliano MD<sup>1</sup>, Giusi Grimaldi MD<sup>1</sup>, Maria  
Teresa Guarino MD<sup>1</sup>, Rosa Musto MD<sup>1</sup>, Camilla Czaczkes  
MD<sup>1</sup>, Michele Cavaliere, MD PhD<sup>1</sup>, Massimo Mesolella, MD  
PhD<sup>1</sup> e Maurizio Iengo, MD<sup>1</sup>.

<sup>1</sup>Division of Otolaryngology-Head and Neck Surgery, Department of Neuroscience, Reproductive and Odontostomatologic Sciences, University of Naples Federico II. Pansini Street n.5, 80131; Naples, Italy.

<sup>2</sup>CEINGE- Advanced Biotechnology, Salvatore G. Street n.486, 80131; Naples, Italy.

<sup>3</sup>Adult Cystic Fibrosis Center, Department of Translational Medical Sciences, University of Naples Federico II. Pansini Street n.5, 80131; Naples, Italy

<sup>4</sup>Department of Public Health, University of Naples Federico II. Pansini Street n.5, 80131; Naples, Italy.

Cystic Fibrosis (CF) involves the upper airways with chronic rhinosinusitis (CRS) causing nasal congestion, rhinorrhea, mouth breathing, facial pain, and olfactory dysfunction. Twelve to 71% of CF patients report smelling alterations impacting nutrition and quality of life. The aim was to study olfaction performance in CF patients with CRS that worsens quality of life. One hundred and twenty-one subjects were enrolled in this study. Seventy-one had CF and underwent ear, nose, and throat evaluation with nasal endoscopy, SNOT-22, VAS and “Sniffin’ Sticks”. Fifty subjects were age-matched with healthy controls. All 71 CF patients were affected by CRS; 59/71 (83.1%) had CRS without nasal polyps and 12/71 (16.9%) had CRS with early nasal polyps. None of the 50 controls had CRS. Total SNOT-22 mean values in the 71 CF patients was  $38.10 \pm 21.08$  pts. If considering only the 59 CF patients without nasal polyps the SNOT-22 mean value was  $36.76 \pm 21.52$  pts. Moreover, based on the VAS scores, the degree of nasal symptoms was classified as mild for facial pain, smell alteration, nasal discharge, and sneezing and resulted in moderate symptoms for nasal blockage and headache. Among the CF patients, 55/71 (76.5%) declared normosmia while the smelling ability assessed by “Sniffin’ Sticks” showed that only 4/71 (5.63%) were normosmic, 58 (81.69%) were hyposmic, and 9 (12.68%) were anosmic. In the controls 41(82%) were normosmic, 9 (18%) were hyposmic, and none were reported anosmia ( $p < 0.001$ ). The study confirms that most CF patients have a relevant olfactory impairment, although only a low percentage declare it. A careful evaluation with simple and rapid tests helps to select the patients that may benefit from specific therapies.